VDVasily N. Dobrovolsky

Vasily N. Dobrovolsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vasily N. Dobrovolsky has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Robert H. Heflich

    Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration

    15 shared publications
  • Mason G. Pearce

    Division of Genetic and Molecular Toxicology National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA) Jefferson Arkansas USA

    9 shared publications
  • Joseph G. Shaddock

    Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration

    8 shared publications
  • Roberta A. Mittelstaedt

    Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration

    7 shared publications
  • Javier Revollo

    Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, United States

    6 shared publications
  • Timothy W. Robison

    Office of New Drugs, OII, DPTII, Center for Drug Evaluation and Research (CDER), US FDA Silver Spring Maryland USA

    6 shared publications

Latest Publications

  • Open Access

    Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans

    by Page B McKinzie, Rutu R Valapil, Emily L Heil, James E Polli, Meagan B Myers, Mason G Pearce, Vasily N Dobrovolsky

    Molnupiravir (MOV) is a prodrug of N-hydroxycytidine (NHC), an analog of the endogenous ribonucleoside cytidine that can be administered orally. MOV is used for treating patients infected by SARS-CoV-2, the coronavirus responsible for COVID-19. MOV and NHC are mutagenic in bacterial and in mammalian cell cultures, yet both chemicals have been negative or equivocal in nonclinical in vivo models of mutagenesis. We designed and validated a novel error-corrected sequencing (ECS) method for detecting single basepair substitutions in tissue samples obtained from genetically heterogeneous humans. The software used for this ECS method is available for free from a public online repository and it is suitable for analysis of in vivo and in vitro derived samples collected in various experimental scenarios. We recruited two groups of patients having COVID-19 1–3 years ago, one group that received a full course of MOV therapy and the other group (matched for age and COVID-19 diagnosis date) that did not receive MOV. Using the ECS method, we determined the frequencies of basepair substitutions in nucleated cells isolated from peripheral blood of the patients. There was no observed difference in the frequency of mutations, the types of mutations, or mutational spectra between the MOV and the control groups. Also, the spectra of mutations in the MOV group did not show any evidence of the mutational signature expected from exposures to MOV or NHC based on data from mammalian cell culture models. Within the limits of this study, the dose of MOV authorized for the treatment of COVID-19 under emergency use authorization appears to have no mutational consequences for treated patients.

  • Detection of In Vivo Mutation in the Hprt and Pig-a Genes of Rat Lymphocytes

    by Vasily N. Dobrovolsky, Joseph G. Shaddock, Roberta A. Mittelstaedt, Daishiro Miura, Robert H. Heflich

    Assays for in vivo mutation are used to identify genotoxic hazards and phenotypes prone to genomic instability and cancer. The hypoxanthine guanine phosphoribosyl transferase (Hprt) gene and the phosphatidyl inositol glycan, class A, (Pig-a) gene are endogenous X-linked genes that can be used as reporters of mutation in peripheral blood lymphocytes from most mammals. Here we describe methodology for measuring Hprt and Pig-a mutation in rat T-lymphocytes. The identification and selective expansion of mutant lymphocytes is based upon the phenotypic properties of Hprt- and Pig-a-deficient cells, i.e., resistance to the purine analog, 6-thioguanine, or to the bacterial toxin, proaerolysin. Expanded mutants can be further analyzed by sequencing cDNA from the target transcripts for identification of small sequence alterations and by multiplex PCR analysis of genomic DNA for the detection of deletions.

  • Open Access

    Application of error-corrected sequencing technologies for in vivo regulatory mutagenicity assessment

    by Carole L. Yauk, Anthony M. Lynch, Vasily N. Dobrovolsky, Maik Schuler, Stephanie L. Smith-Roe, Devon Fitzgerald, Jake Higgins, Naveed Honarvar, Frank Le Curieux, Shoji Matsumura, et al.


  • Open Access

    Erythrocyte PIG‐A mutant frequencies in cancer patients receiving cisplatin

    by Vasily N. Dobrovolsky, Omar T. Atiq, Robert H. Heflich, Mackean Maisha, Page B. McKinzie, Mason G. Pearce, Timothy W. Robison

    Background: Cisplatin is a primary chemotherapy choice for various solid tumors. DNA damage caused by cisplatin results in apoptosis of tumor cells. Cisplatin‐induced DNA damage, however, may also result in mutations in normal cells and the initiation of secondary malignancies. In the current study, we have used the erythrocyte PIG‐A assay to evaluate mutagenesis in non‐tumor hematopoietic tissue of cancer patients receiving cisplatin chemotherapy.Methods: Twenty‐one head and neck cancer patients undergoing treatment with cisplatin were monitored for the presence of PIG‐A mutant total erythrocytes and the young erythrocytes, reticulocytes (RETs), in peripheral blood for up to five and a half months from the initiation of the anti‐neoplastic chemotherapy.Results: PIG‐A mutant frequency (MF) in RETs increased at least two‐fold in 15 patients at some point of the monitoring, while the frequency of total mutant RBCs increased at least two‐fold in 6 patients. A general trend for an increase in the frequency of mutant RETs and total mutant RBCs was observed in 19 and 18 patients, respectively. Only in one patient did both RET and total RBC PIG‐A MFs did not increase at any time‐point over the monitoring period.Conclusion: Cisplatin chemotherapy induces moderate increases in the frequency of PIG‐A mutant erythrocytes in head and neck cancer patients. Mutagenicity measured with the flow cytometric PIG‐A assay may serve as a tool for predicting adverse outcomes of genotoxic antineoplastic therapy.


  • Mutational signatures in T‐lymphocytes of rats treated with N‐propyl‐N‐nitrosourea and procarbazine

    by Javier R. Revollo, Page B. McKinzie, Timothy W. Robison, Vasily N. Dobrovolsky

    We have used whole genome sequencing (WGS) to determine mutational signatures induced in the T-cells of rats treated in vivo with N-propyl-N-nitrosourea (PNU) or procarbazine (PCZ). The signatures from the treated rats were different from the signature of background mutations. The main component of the spontaneous T-cell mutational signature was C➔T transition with all other single base substitutions evenly distributed. The PNU-induced mutational signature showed relatively equal contributions from C➔T and T➔C transitions, and T➔A transversions. The PCZ-induced signature was characterized by T➔C transitions, T➔A and, to a smaller extent, T➔G transversions. C➔G transversions were infrequent in either the PNU or PCZ signatures. WGS not only allowed mutational signature detection, but also measured quantitative responses to mutagen treatment: 10–40× increases in the number of mutations per clone were detected in T-cell clones from treated rats. The overall strand specificity of induced mutations for annotated rat genes was comparable to the strand specificity of mutations determined previously for the endogenous X-linked Pig-a gene. Our results provide valuable reference data for future applications of WGS in safety research and risk assessment.


  • CD59‐deficient bone marrow erythroid cells from rats treated with procarbazine and propyl‐nitrosourea have mutations in thePig‐agene

    by Javier R. Revollo, Azra Dad, Mason G. Pearce, Roberta A. Mittelstaedt, Andrea Casildo, Rena G. Lapidus, Timothy W. Robison, Vasily N. Dobrovolsky

    Procarbazine (PCZ) andN‐propyl‐N‐nitrosourea (PNU) are rodent mutagens and carcinogens. Both induce GPI‐anchored marker‐deficient mutant‐phenotype red blood cells (RBCs) in the flow cytometry‐based rat RBCPig‐aassay. In the present study, we traced the origin of the RBC mutant phenotype by analyzingPig‐amutations in the precursors of RBCs, bone marrow erythroid cells (BMEs). Rats were exposed to a total of 450 mg/kg PCZ hydrochloride or 300 mg/kg PNU, and bone marrow was collected 2, 7, and 10 weeks later. Using a flow cell sorter, we isolated CD59‐deficient mutant‐phenotype BMEs from PCZ‐ and PNU‐treated rats and examined their endogenous X‐linkedPig‐agene by next generation sequencing.Pig‐amutations consistent with the properties of PCZ and PNU were found in sorted mutant‐phenotype BMEs. PCZ induced mainly A > T transversions with the mutated A on the nontranscribed strand of thePig‐agene, while PNU induced mainly T > A transversions with the mutated T on the nontranscribed strand. The treatment‐induced mutations were distributed across the protein coding sequence of thePig‐agene. The causal relationship between BMEs and RBCs and the agent‐specific mutational spectra in CD59‐deicient BMEs indicate that the rat RBCPig‐aassay, scoring CD59‐deficient mutant‐phenotype RBCs in peripheral blood, detectsPig‐agene mutation.


  • Detection of Pig-a Mutant Erythrocytes in the Peripheral Blood of Rats and Mice

    by Vasily N. Dobrovolsky, Xuefei Cao, Javed A. Bhalli, Robert H. Heflich

    The endogenous X-linked phosphatidyl inositol glycan class A gene (Pig-a) can be used as a reporter of in vivo somatic cell mutation in rats and mice. Pig-a mutant cells are deficient in specific protein surface markers and can be identified and quantified by immunofluorescent staining followed by high-throughput flow cytometry. Pig-a mutation detection is commonly performed with red blood cells (RBCs) because: (1) the low volumes of blood required for determining mutant frequencies in RBCs allow multiple samplings on small laboratory animals over extended periods of time; (2) the execution of the RBC assay is easy and the interpretation of the results is straightforward; and (3) RBC Pig-a mutant frequencies are known within hours of sample collection. Two endpoints are determined in the assay: the frequency of mutant total RBCs and the frequency of mutant reticulocytes. When Pig-a mutation is used to assess the in vivo mutagenic potential of suspect hazards, the frequency of mutant reticulocytes is an early indicator of mutagenic potential, while the mutant frequency in total RBCs can be measured more rapidly and with greater precision.


  • Analysis of In Vivo Mutation in the Hprt and Tk Genes of Mouse Lymphocytes

    by Vasily N. Dobrovolsky, Joseph G. Shaddock, Robert H. Heflich

    Determining mutant frequencies in endogenous reporter genes is a tool for identifying potentially genotoxic environmental agents, and discovering phenotypes prone to genomic instability and diseases, such as cancer. Here, we describe a high-throughput method for identifying mouse spleen lymphocytes with mutations in the endogenous X-linked hypoxanthine guanine phosphoribosyl transferase (Hprt) gene and the endogenous autosomal thymidine kinase (Tk) gene. The selective clonal expansion of mutant lymphocytes is based upon the phenotypic properties of HPRT- and TK-deficient cells. The same procedure can be utilized for quantifying Hprt mutations in most strains of mice (and, with minor changes, in other mammalian species), while mutations in the Tk gene can be determined only in transgenic mice that are heterozygous for inactivation of this gene. Expanded mutant clones can be further analyzed to classify the types of mutations in the Tk gene (small intragenic mutations vs. large chromosomal mutations) and to determine the nature of intragenic mutation at both the Hprt and Tk genes.


  • Pig-a mutations in bone marrow erythroblasts of rats treated with 7,12-dimethyl-benz[a]anthracene

    by Javier R. Revollo, Azra Dad, Mason G. Pearce, Roberta A. Mittelstaedt, Timothy W. Robison, Vasily N. Dobrovolsky